InsiderTrades.com logo
This Crypto Is Set to Explode in December
From Crypto 101 Media   |   Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW

SKYE Insider Trading

Insider Ownership Percentage: 3.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,910,712.67

Skye Bioscience Insider Trading History Chart

This chart shows the insider buying and selling history at Skye Bioscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Skye Bioscience Share Price & Price History

Current Price: $2.70
Price Change: ▼ Price Decrease of -0.16 (-5.59%)
As of 12/20/2024 09:57 PM ET

This chart shows the closing price history over time for SKYE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits   |   Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin

Skye Bioscience Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2024Kaitlyn ArsenaultCFOSell43,206$4.99$215,597.94166,342View SEC Filing Icon  
11/18/2024Paul A GraysonDirectorSell86,244$4.99$430,357.56259,701View SEC Filing Icon  
11/18/2024Punit DhillonCEOSell82,546$4.99$411,904.54329,823View SEC Filing Icon  
11/18/2024Tuan Tu DiepInsiderSell19,489$4.99$97,250.1182,259View SEC Filing Icon  
11/15/2024Kaitlyn ArsenaultCFOSell190$5.55$1,054.50209,548View SEC Filing Icon  
11/15/2024Paul A GraysonDirectorSell307$5.55$1,703.85345,945View SEC Filing Icon  
11/15/2024Punit DhillonCEOSell364$5.55$2,020.20412,369View SEC Filing Icon  
11/15/2024Tuan Tu DiepInsiderSell85$5.55$471.75101,748View SEC Filing Icon  
9/13/2024Andrew J SchwabDirectorSell13,837$6.06$83,852.2266,277View SEC Filing Icon  
9/11/2024Andrew J SchwabDirectorSell252,500$6.60$1,666,500.0066,356View SEC Filing Icon  
See Full Table
This Crypto Is Set to Explode in December
From Crypto 101 Media   |   Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW

SEC Filings (Institutional Ownership Changes) for Skye Bioscience (NASDAQ:SKYE)

21.09% of Skye Bioscience stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SKYE by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Skye Bioscience Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/19/2024Barclays PLC57,889$0.23M0.0%+36.7%0.191%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC385,793$1.51M0.0%+4.2%1.272%Search for SEC Filing on Google Icon
11/15/2024Barclays PLC57,889$0.23M0.0%+36.7%0.191%Search for SEC Filing on Google Icon
11/15/2024Jane Street Group LLC12,200$48K0.0%N/A0.040%Search for SEC Filing on Google Icon
11/15/2024Sphera Funds Management LTD.1,563,522$6.11M1.0%+20.4%5.153%Search for SEC Filing on Google Icon
11/15/2024State Street Corp354,205$1.39M0.0%+7.0%1.167%Search for SEC Filing on Google Icon
11/15/2024Point72 Asset Management L.P.416,424$1.63M0.0%-25.6%1.373%Search for SEC Filing on Google Icon
11/15/2024Baker BROS. Advisors LP1,434,634$5.61M0.1%+186.9%4.729%Search for SEC Filing on Google Icon
11/13/2024BNP Paribas Financial Markets47,417$0.19M0.0%+71.1%0.156%Search for SEC Filing on Google Icon
9/16/2024Point72 DIFC Ltd6,000$48K0.0%N/A0.021%Search for SEC Filing on Google Icon
9/16/2024Cubist Systematic Strategies LLC3,762$30K0.0%N/A0.013%Search for SEC Filing on Google Icon
9/16/2024Point72 Asia Singapore Pte. Ltd.27,768$0.22M0.0%N/A0.099%Search for SEC Filing on Google Icon
8/19/2024Point72 Asset Management L.P.560,000$4.49M0.0%N/A1.995%Search for SEC Filing on Google Icon
8/16/2024Perceptive Advisors LLC500,000$4.01M0.1%N/A1.781%Search for SEC Filing on Google Icon
8/16/2024Driehaus Capital Management LLC650,758$5.21M0.0%N/A2.319%Search for SEC Filing on Google Icon
8/15/2024CVI Holdings LLC679,739$5.45M4.9%N/A2.422%Search for SEC Filing on Google Icon
8/15/2024Point72 Asia Singapore Pte. Ltd.27,768$0.22M0.0%N/A0.099%Search for SEC Filing on Google Icon
8/14/2024Cubist Systematic Strategies LLC3,762$30K0.0%N/A0.013%Search for SEC Filing on Google Icon
8/14/2024Point72 DIFC Ltd6,000$48K0.0%N/A0.021%Search for SEC Filing on Google Icon
8/14/2024Logos Global Management LP1,301,518$10.43M0.8%N/A4.637%Search for SEC Filing on Google Icon
8/8/2024AdvisorShares Investments LLC26,000$0.21M0.0%N/A0.093%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers19,754$0.16M0.0%N/A0.070%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp58,778$0.47M0.0%N/A0.209%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Skye Bioscience logo
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Read More on Skye Bioscience

Today's Range

Now: $2.70
Low: $2.66
High: $3.09

50 Day Range

MA: $3.84
Low: $2.70
High: $4.56

52 Week Range

Now: $2.70
Low: $2.25
High: $19.41

Volume

484,700 shs

Average Volume

180,317 shs

Market Capitalization

$81.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72

Who are the company insiders with the largest holdings of Skye Bioscience?

Skye Bioscience's top insider shareholders include:
  1. Punit Dhillon (CEO)
  2. Paul A Grayson (Director)
  3. Kaitlyn Arsenault (CFO)
  4. Tuan Tu Diep (Insider)
  5. Andrew J Schwab (Director)
Learn More about top insider investors at Skye Bioscience.

Who are the major institutional investors of Skye Bioscience?

Skye Bioscience's top institutional investors include:
  1. Sphera Funds Management LTD. — 5.15%
  2. Baker BROS. Advisors LP — 4.73%
  3. Point72 Asset Management L.P. — 1.37%
  4. Geode Capital Management LLC — 1.27%
  5. State Street Corp — 1.17%
  6. Barclays PLC — 0.19%
Learn More about top institutional investors of Skye Bioscience stock.

Which institutional investors are selling Skye Bioscience stock?

In the last quarter, SKYE stock was sold by these institutional investors:
  1. Point72 Asset Management L.P.
During the previous year, company insiders that have sold Skye Bioscience company stock include:
  1. Punit Dhillon (CEO)
  2. Paul A Grayson (Director)
  3. Kaitlyn Arsenault (CFO)
  4. Tuan Tu Diep (Insider)
  5. Andrew J Schwab (Director)
Learn More investors selling Skye Bioscience stock.

Which institutional investors are buying Skye Bioscience stock?

In the previous quarter, SKYE stock was acquired by institutional investors including:
  1. Baker BROS. Advisors LP
  2. Sphera Funds Management LTD.
  3. State Street Corp
  4. BNP Paribas Financial Markets
  5. Geode Capital Management LLC
  6. Barclays PLC
  7. Barclays PLC
  8. Jane Street Group LLC
This Crypto Is Set to Explode in December
From Crypto 101 Media   |   Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW